Cd11b and Cd56 as Prognostic Markers in Acute Myeloid Leukemia

September 12, 2017 updated by: Z A Kamel, Assiut University
  1. Detect the expression of marker CD56 and CD11b in newly diagnosed cases of adult AML.
  2. Study correlation between CD56 and CD11b expression with haematological parameters in cases of adult AML.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

  1. CD11b expression level is a prognostic biomarker for AML patient. CD11b positivity could predict a poor prognosis for AML patients.
  2. CD56 antigen expression, an inexpensive, easy to detect and reproduce index, is closely related to the prognosis of AML patients

Study Type

Observational

Enrollment (Anticipated)

30

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years to 48 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Anew diagnosis cases of adult AML

Description

Inclusion Criteria:

Anew diagnosis cases of adult AML

Exclusion Criteria:

  1. Pediatric AML .
  2. follow up cases of adult AML

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Control
  • Time Perspectives: Cross-Sectional

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
CD11b and CD56 markers
Cd11b and Cd56 as Prognostic Markers in Acute Myeloid Leukemia
Diagnostic test: Cd11b and Cd56 markers
The expression of CD11b and CD56 in newly diadnosed cases of AML
Other Names:
  • Cd11b and Cd56 as Prognostic Markers in Acute Myeloid Leukemia
Haematological parameters in cases of adult AML
Study correlation between CD56 and CD11b expression with haematological parameters in cases of adult AML
Diagnostic test: Cd11b and Cd56 markers
The expression of CD11b and CD56 in newly diadnosed cases of AML
Other Names:
  • Cd11b and Cd56 as Prognostic Markers in Acute Myeloid Leukemia

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
CD11b and CD56 marker
Time Frame: 24 month
Detect the expression of marker CD56 and CD11b in newly diagnosed cases of adult AML.
24 month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Assiut University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

December 1, 2017

Primary Completion (Anticipated)

December 1, 2018

Study Completion (Anticipated)

October 1, 2019

Study Registration Dates

First Submitted

August 27, 2017

First Submitted That Met QC Criteria

September 12, 2017

First Posted (Actual)

September 14, 2017

Study Record Updates

Last Update Posted (Actual)

September 14, 2017

Last Update Submitted That Met QC Criteria

September 12, 2017

Last Verified

September 1, 2017

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Myeloid Leukemia Markers

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Adult Acute Myeloid Leukemia

Clinical Trials on Cd11b and Cd56 markers

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gabon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe